Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Corbus Pharma (CRBP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 299,985
  • Shares Outstanding, K 57,140
  • Annual Sales, $ 2,440 K
  • Annual Income, $ -32,420 K
  • 36-Month Beta 2.24
  • Price/Sales 122.95
  • Price/Cash Flow N/A
  • Price/Book 4.58

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.85 +7.73%
on 06/28/18
6.10 -14.34%
on 06/21/18
-0.83 (-13.64%)
since 06/19/18
3-Month
4.85 +7.73%
on 06/28/18
6.80 -23.16%
on 04/23/18
-1.53 (-22.59%)
since 04/19/18
52-Week
4.85 +7.73%
on 06/28/18
9.95 -47.51%
on 01/30/18
-1.33 (-20.23%)
since 07/19/17

Most Recent Stories

More News
Vertex's Shares Rally as a Rival's CF Candidate Disappoints

Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.

CRBP : 5.22 (-0.48%)
VRTX : 179.14 (-1.10%)
ABBV : 88.95 (-5.77%)
GLPG : 103.54 (+1.40%)
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference

The New York Academy of Sciences symposium will highlight cutting edge research across the fields of inflammation, infection, and tissue regeneration, with focus on novel resolution mediators and mechanisms...

CRBP : 5.22 (-0.48%)
Corbus Pharmaceuticals to Present at the JMP Securities Life Science Conference

- Live fireside chat webcast on Wednesday, June 20 at 2:30 p.m. EDT -

CRBP : 5.22 (-0.48%)
Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018

-- Multiple key efficacy outcomes further improved in open-label extensions of systemic sclerosis (SSc) and dermatomyositis (DM) Phase 2 studies

CRBP : 5.22 (-0.48%)
A Promising Big Step Forward for Medical Marijuana

MarketNewsUpdates.com Market Commentary

SCCYF : 2.8400 (-3.86%)
CRBP : 5.22 (-0.48%)
APH.TO : 11.17 (-0.71%)
SCYB.VN : 3.740 (-5.79%)
APHQF : 8.4300 (-1.32%)
OGRMF : 3.4901 (-1.96%)
ABBV : 88.95 (-5.77%)
OGI.VN : 4.640 (-0.22%)
Research Report Identifies Corbus Pharmaceuticals, Retrophin, Charter Financial, HighPoint Resources, Southern First Bancshares, and Oaktree Specialty Lending with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Corbus Pharmaceuticals Holdings,...

CRBP : 5.22 (-0.48%)
CHFN : 24.02 (-0.41%)
SFST : 44.50 (+0.34%)
OCSL : 4.76 (-0.42%)
HPR : 6.61 (+0.92%)
RTRX : 30.81 (-2.50%)
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors

- Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND -

CRBP : 5.22 (-0.48%)
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

- Live audio presentation and webcast on Wednesday, June 6 at 9:00 a.m. EDT -

CRBP : 5.22 (-0.48%)
Cannabis is Fueling the Next Era of Medical Revolution

Marketnewsupdates.com News Commentary

SCCYF : 2.8400 (-3.86%)
CRBP : 5.22 (-0.48%)
SCYB.VN : 3.740 (-5.79%)
APH.TO : 11.17 (-0.71%)
APHQF : 8.4300 (-1.32%)
GWPH : 149.06 (+0.12%)
OGRMF : 3.4901 (-1.96%)
OGI.VN : 4.640 (-0.22%)
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting

- Data from Phase 2 one-year open-label extension of lenabasum in systemic sclerosis and 6-month open-label extension data in dermatomyositis studies to be presented -

CRBP : 5.22 (-0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CRBP with:

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

2nd Resistance Point 5.35
1st Resistance Point 5.30
Last Price 5.22
1st Support Level 5.15
2nd Support Level 5.05

See More

52-Week High 9.95
Fibonacci 61.8% 8.00
Fibonacci 50% 7.40
Fibonacci 38.2% 6.80
Last Price 5.22
52-Week Low 4.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar